FDA May Decide on New Use For AbbVie’s Humira

by Andrew Berens, Grace Guo, Bloomberg Industries

 

AbbVie’s supplemental Biologics License Application (sBLA) to expand Humira’s existing approval for ankylosing spondylitis to include the treatment of non-radiographic axial spondyloarthritis has an estimated PDUFA date of Sept. 29.

 

Read more>>>

Bloomberg BRIEF Newsletters